These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
304 related items for PubMed ID: 1545850
1. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR. N Engl J Med; 1992 Apr 09; 326(15):975-82. PubMed ID: 1545850 [Abstract] [Full Text] [Related]
2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. N Engl J Med; 1996 Mar 14; 334(11):682-7. PubMed ID: 8594426 [Abstract] [Full Text] [Related]
3. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. N Engl J Med; 1996 Mar 14; 334(11):677-81. PubMed ID: 8594425 [Abstract] [Full Text] [Related]
4. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. N Engl J Med; 2001 Mar 01; 344(9):626-31. PubMed ID: 11228276 [Abstract] [Full Text] [Related]
5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Arch Intern Med; 1993 Jul 12; 153(13):1541-6. PubMed ID: 8391792 [Abstract] [Full Text] [Related]
11. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Arch Intern Med; 2004 May 24; 164(10):1077-83. PubMed ID: 15159264 [Abstract] [Full Text] [Related]
15. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost; 1991 Mar 04; 65(3):251-6. PubMed ID: 1646490 [Abstract] [Full Text] [Related]
19. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. N Engl J Med; 1997 Aug 14; 337(7):447-52. PubMed ID: 9250846 [Abstract] [Full Text] [Related]
20. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL. Semin Thromb Hemost; 1997 Aug 14; 23(1):83-90. PubMed ID: 9156415 [Abstract] [Full Text] [Related] Page: [Next] [New Search]